Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.98 |
| ▸ | F2 | P00734 | 3/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78826 | 1.00 | F10 (0.98) | F10F2ABCB11ST14 | |
| SCHEMBL76970 | 0.99 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL79284 | 0.99 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL79715 | 0.92 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL77506 | 0.91 | F10 (0.85) | F10F2ABCB11ST14 | |
| SCHEMBL15500481 | 0.90 | F10 (0.80) | F10F2ABCB11ST14 | |
| SCHEMBL77471 | 0.89 | F10 (0.94) | F10F2ABCB11ST14 | |
| SCHEMBL77773 | 0.89 | F10 (0.82) | F10F2ABCB11ST14 | |
| SCHEMBL78408 | 0.89 | F10 (0.82) | F10F2ABCB11ST14 | |
| SCHEMBL78302 | 0.88 | F10 (0.86) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576111-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885F2 1/4885ABCB11 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.